BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldenberg NM, Rabinovitch M, Steinberg BE. Inflammatory Basis of Pulmonary Arterial Hypertension: Implications for Perioperative and Critical Care Medicine. Anesthesiology 2019;131:898-907. [PMID: 31094755 DOI: 10.1097/ALN.0000000000002740] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Scott TE, Qin CX, Drummond GR, Hobbs AJ, Kemp-Harper BK. Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019. Hypertension 2021;78:1168-84. [PMID: 34565184 DOI: 10.1161/HYPERTENSIONAHA.120.14525] [Reference Citation Analysis]
2 Montagnoli TL, da Silva JS, Sudo SZ, Santos AD, Gomide GF, de Sá MPL, Zapata-Sudo G. ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension. Cells 2021;10:1648. [PMID: 34209333 DOI: 10.3390/cells10071648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Funk-hilsdorf TC, Behrens F, Grune J, Simmons S. Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer. Front Physiol 2022;13:819145. [DOI: 10.3389/fphys.2022.819145] [Reference Citation Analysis]
4 Zemskova M, McClain N, Niihori M, Varghese MV, James J, Rafikov R, Rafikova O. Necrosis-Released HMGB1 (High Mobility Group Box 1) in the Progressive Pulmonary Arterial Hypertension Associated With Male Sex. Hypertension 2020;76:1787-99. [PMID: 33012199 DOI: 10.1161/HYPERTENSIONAHA.120.16118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 King NE, Brittain E. Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulm circ 2022;12. [DOI: 10.1002/pul2.12028] [Reference Citation Analysis]
6 Yu Z, Xiao J, Chen X, Ruan Y, Chen Y, Zheng X, Wang Q. Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension. Chin Med 2022;17. [DOI: 10.1186/s13020-022-00568-w] [Reference Citation Analysis]
7 Hu Y, Chi L, Kuebler WM, Goldenberg NM. Perivascular Inflammation in Pulmonary Arterial Hypertension. Cells 2020;9:E2338. [PMID: 33105588 DOI: 10.3390/cells9112338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Ito T, Zhang E, Omori A, Kabwe J, Kawai M, Maruyama J, Okada A, Yokochi A, Sawada H, Mitani Y, Maruyama K. Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats. BMC Pulm Med 2021;21:377. [PMID: 34801000 DOI: 10.1186/s12890-021-01710-4] [Reference Citation Analysis]
9 Feng W, Wang J, Yan X, Zhang Q, Chai L, Wang Q, Shi W, Chen Y, Liu J, Qu Z, Li S, Xie X, Li M. ERK/Drp1-dependent mitochondrial fission contributes to HMGB1-induced autophagy in pulmonary arterial hypertension. Cell Prolif 2021;54:e13048. [PMID: 33948998 DOI: 10.1111/cpr.13048] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Yang X, Wang C, Lin Y, Zhang P. Identification of Crucial Hub Genes and Differential T Cell Infiltration in Idiopathic Pulmonary Arterial Hypertension Using Bioinformatics Strategies. Front Mol Biosci 2022;9:800888. [DOI: 10.3389/fmolb.2022.800888] [Reference Citation Analysis]